Gorse, G.J.Baden, L.R.Wecker, M.Newman, M.J.Ferrari, G.Weinhold, K.J.Livingston, B.D.Villafana, T.L.Li, H.Noonan, E.Russell, N.D.2012-12-312017-10-192012-12-312017-10-19200826(2):215-23http://197.255.68.203/handle/123456789/2076We evaluated EP HIV-1090 vaccine, a DNA plasmid encoding 21 cytotoxic T-lymphocyte (CTL) epitopes of human immunodeficiency virus type 1 (HIV-1) and the pan-DR helper T-lymphocyte epitope (PADRE), in a dose escalation, randomized, double-blinded, placebo-controlled Phase 1 trial. Vaccine, at 0.5, 2.0, or 4.0mg doses, or placebo was injected four times over 6 months. Forty-two healthy, HIV-1-uninfected adults were enrolled. Using an interferon-gamma ELISPOT assay, a response to PADRE was detected in one vaccine recipient. Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic.enArticle